{
    "LUPIN": {
        "Title": "Lupin Ltd share price | About Lupin | Key Insights - Screener",
        "CompanyName": "Lupin Ltd",
        "Link": "https://www.lupin.com",
        "NSECode": "LUPIN",
        "BSECode": "500257",
        "AboutCompany": "Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.",
        "MarketCap": "87604",
        "P/ERatio": "23.7",
        "ROE": "20.6",
        "ROCE": "21.3",
        "DividendYeild": "0.63",
        "BookValue": "377",
        "LastPrice": "1918",
        "LastPriceChange": -1.35,
        "LastPriceChangeDate": "08 Aug",
        "High": "2,403",
        "Low": "1,774",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "24810"
            ],
            [
                "Mar 2021",
                "23430"
            ],
            [
                "Mar 2022",
                "21651"
            ],
            [
                "Mar 2023",
                "22800"
            ],
            [
                "Mar 2024",
                "23751"
            ],
            [
                "Mar 2025",
                "28978"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Mar 2024",
                "368"
            ],
            [
                "Jun 2024",
                "806"
            ],
            [
                "Sep 2024",
                "859"
            ],
            [
                "Dec 2024",
                "859"
            ],
            [
                "Mar 2025",
                "782"
            ],
            [
                "Jun 2025",
                "1221"
            ]
        ],
        "PROs": [
            "Company has delivered good profit growth of 54.9% CAGR over last 5 years",
            "Company has been maintaining a healthy dividend payout of 26.0%"
        ],
        "CONs": [
            "Stock is trading at 5.09 times its book value",
            "The company has delivered a poor sales growth of 8.11% over past five years.",
            "Company has a low return on equity of 13.4% over last 3 years."
        ]
    },
    "ABBOTINDIA": {
        "Title": "Abbott India Ltd share price | About Abbott India | Key Insights - Screener",
        "CompanyName": "Abbott India Ltd",
        "Link": "http://www.abbott.co.in",
        "NSECode": "ABBOTINDIA",
        "BSECode": "500488",
        "AboutCompany": "Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.It was established in 1944.",
        "MarketCap": "69796",
        "P/ERatio": "49.3",
        "ROE": "35.7",
        "ROCE": "46.2",
        "DividendYeild": "1.45",
        "BookValue": "1,992",
        "LastPrice": "32845",
        "LastPriceChange": 0.38,
        "LastPriceChangeDate": "08 Aug",
        "High": "37,000",
        "Low": "25,260",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "3547"
            ],
            [
                "Mar 2021",
                "3840"
            ],
            [
                "Mar 2022",
                "4224"
            ],
            [
                "Mar 2023",
                "4556"
            ],
            [
                "Mar 2024",
                "5193"
            ],
            [
                "Mar 2025",
                "5917"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Dec 2023",
                "311"
            ],
            [
                "Mar 2024",
                "287"
            ],
            [
                "Jun 2024",
                "328"
            ],
            [
                "Sep 2024",
                "359"
            ],
            [
                "Dec 2024",
                "361"
            ],
            [
                "Mar 2025",
                "367"
            ]
        ],
        "PROs": [
            "Company is almost debt free.",
            "Company has delivered good profit growth of 19.0% CAGR over last 5 years",
            "Company has a good return on equity (ROE) track record: 3 Years ROE 34.2%",
            "Company has been maintaining a healthy dividend payout of 72.2%"
        ],
        "CONs": [
            "Stock is trading at 16.5 times its book value",
            "The company has delivered a poor sales growth of 9.38% over past five years.",
            "Working capital days have increased from 24.9 days to 97.2 days"
        ]
    },
    "AUROPHARMA": {
        "Title": "Aurobindo Pharma Ltd share price | About Aurobindo Pharma | Key Insights - Screener",
        "CompanyName": "Aurobindo Pharma Ltd",
        "Link": "http://www.aurobindo.com",
        "NSECode": "AUROPHARMA",
        "BSECode": "524804",
        "AboutCompany": "Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)",
        "MarketCap": "61061",
        "P/ERatio": "18.0",
        "ROE": "11.2",
        "ROCE": "14.3",
        "DividendYeild": "0.43",
        "BookValue": "557",
        "LastPrice": "1042",
        "LastPriceChange": -2.57,
        "LastPriceChangeDate": "08 Aug",
        "High": "1,593",
        "Low": "994",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "28765"
            ],
            [
                "Mar 2021",
                "33416"
            ],
            [
                "Mar 2022",
                "33638"
            ],
            [
                "Mar 2023",
                "39505"
            ],
            [
                "Mar 2024",
                "44717"
            ],
            [
                "Mar 2025",
                "49785"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Mar 2024",
                "907"
            ],
            [
                "Jun 2024",
                "918"
            ],
            [
                "Sep 2024",
                "817"
            ],
            [
                "Dec 2024",
                "846"
            ],
            [
                "Mar 2025",
                "903"
            ],
            [
                "Jun 2025",
                "824"
            ]
        ],
        "PROs": [],
        "CONs": [
            "The company has delivered a poor sales growth of 6.55% over past five years.",
            "Company has a low return on equity of 10.2% over last 3 years.",
            "Company might be capitalizing the interest cost",
            "Dividend payout has been low at 10.4% of profits over last 3 years"
        ]
    },
    "CIPLA": {
        "Title": "Cipla Ltd share price | About Cipla | Key Insights - Screener",
        "CompanyName": "Cipla Ltd",
        "Link": "http://www.cipla.com",
        "NSECode": "CIPLA",
        "BSECode": "500087",
        "AboutCompany": "Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)",
        "MarketCap": "120016",
        "P/ERatio": "22.3",
        "ROE": "17.8",
        "ROCE": "22.7",
        "DividendYeild": "0.87",
        "BookValue": "386",
        "LastPrice": "1486",
        "LastPriceChange": -0.35,
        "LastPriceChangeDate": "08 Aug",
        "High": "1,702",
        "Low": "1,310",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "23423"
            ],
            [
                "Mar 2021",
                "24855"
            ],
            [
                "Mar 2022",
                "26857"
            ],
            [
                "Mar 2023",
                "29300"
            ],
            [
                "Mar 2024",
                "32533"
            ],
            [
                "Mar 2025",
                "37334"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Mar 2024",
                "932"
            ],
            [
                "Jun 2024",
                "1175"
            ],
            [
                "Sep 2024",
                "1305"
            ],
            [
                "Dec 2024",
                "1575"
            ],
            [
                "Mar 2025",
                "1214"
            ],
            [
                "Jun 2025",
                "1292"
            ]
        ],
        "PROs": [
            "Company has reduced debt.",
            "Company is almost debt free.",
            "Company has delivered good profit growth of 29.5% CAGR over last 5 years",
            "Company has been maintaining a healthy dividend payout of 24.8%"
        ],
        "CONs": [
            "The company has delivered a poor sales growth of 9.97% over past five years.",
            "Promoter holding has decreased over last 3 years: -4.42%"
        ]
    },
    "DRREDDY": {
        "Title": "Dr Reddys Laboratories Ltd share price | About Dr Reddy's Labs | Key Insights - Screener",
        "CompanyName": "Dr Reddys Laboratories Ltd",
        "Link": "http://www.drreddys.com",
        "NSECode": "DRREDDY",
        "BSECode": "500124",
        "AboutCompany": "Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.",
        "MarketCap": "101101",
        "P/ERatio": "17.9",
        "ROE": "18.0",
        "ROCE": "22.7",
        "DividendYeild": "0.66",
        "BookValue": "402",
        "LastPrice": "1211",
        "LastPriceChange": 0.88,
        "LastPriceChangeDate": "08 Aug",
        "High": "1,421",
        "Low": "1,020",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "23223"
            ],
            [
                "Mar 2021",
                "26588"
            ],
            [
                "Mar 2022",
                "29746"
            ],
            [
                "Mar 2023",
                "32209"
            ],
            [
                "Mar 2024",
                "38780"
            ],
            [
                "Mar 2025",
                "48023"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Mar 2024",
                "1310"
            ],
            [
                "Jun 2024",
                "1392"
            ],
            [
                "Sep 2024",
                "1342"
            ],
            [
                "Dec 2024",
                "1404"
            ],
            [
                "Mar 2025",
                "1587"
            ],
            [
                "Jun 2025",
                "1410"
            ]
        ],
        "PROs": [
            "Company has delivered good profit growth of 22.3% CAGR over last 5 years",
            "Company's working capital requirements have reduced from 90.5 days to 69.2 days"
        ],
        "CONs": []
    },
    "GLENMARK": {
        "Title": "Glenmark Pharmaceuticals Ltd share price | About Glenmark Pharma. | Key Insights - Screener",
        "CompanyName": "Glenmark Pharmaceuticals Ltd",
        "Link": "http://www.glenmarkpharma.com",
        "NSECode": "GLENMARK",
        "BSECode": "532296",
        "AboutCompany": "Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.",
        "MarketCap": "56993",
        "P/ERatio": "43.2",
        "ROE": "15.8",
        "ROCE": "19.4",
        "DividendYeild": "0.12",
        "BookValue": "314",
        "LastPrice": "2020",
        "LastPriceChange": -2.09,
        "LastPriceChangeDate": "08 Aug",
        "High": "2,286",
        "Low": "1,275",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "14668"
            ],
            [
                "Mar 2021",
                "15575"
            ],
            [
                "Mar 2022",
                "17052"
            ],
            [
                "Mar 2023",
                "19371"
            ],
            [
                "Mar 2024",
                "14358"
            ],
            [
                "Mar 2025",
                "16050"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Dec 2023",
                "-330.81"
            ],
            [
                "Mar 2024",
                "-1214.27"
            ],
            [
                "Jun 2024",
                "340.24"
            ],
            [
                "Sep 2024",
                "354.48"
            ],
            [
                "Dec 2024",
                "348.03"
            ],
            [
                "Mar 2025",
                "4.38"
            ]
        ],
        "PROs": [
            "Company's working capital requirements have reduced from 61.2 days to 44.5 days"
        ],
        "CONs": [
            "Stock is trading at 6.44 times its book value",
            "The company has delivered a poor sales growth of 4.60% over past five years.",
            "Company has a low return on equity of -9.68% over last 3 years."
        ]
    },
    "DIVISLAB": {
        "Title": "Divis Laboratories Ltd share price | About Divi's Lab. | Key Insights - Screener",
        "CompanyName": "Divis Laboratories Ltd",
        "Link": "http://www.divislaboratories.com",
        "NSECode": "DIVISLAB",
        "BSECode": "532488",
        "AboutCompany": "Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients",
        "MarketCap": "157011",
        "P/ERatio": "68.1",
        "ROE": "15.4",
        "ROCE": "20.4",
        "DividendYeild": "0.51",
        "BookValue": "564",
        "LastPrice": "5914",
        "LastPriceChange": -3.54,
        "LastPriceChangeDate": "08 Aug",
        "High": "7,078",
        "Low": "4,616",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "8531"
            ],
            [
                "Mar 2021",
                "10771"
            ],
            [
                "Mar 2022",
                "13360"
            ],
            [
                "Mar 2023",
                "14425"
            ],
            [
                "Mar 2024",
                "15460"
            ],
            [
                "Mar 2025",
                "16921"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Mar 2024",
                "538"
            ],
            [
                "Jun 2024",
                "430"
            ],
            [
                "Sep 2024",
                "510"
            ],
            [
                "Dec 2024",
                "589"
            ],
            [
                "Mar 2025",
                "662"
            ],
            [
                "Jun 2025",
                "545"
            ]
        ],
        "PROs": [
            "Company is almost debt free.",
            "Company has been maintaining a healthy dividend payout of 43.2%"
        ],
        "CONs": [
            "Stock is trading at 10.5 times its book value",
            "The company has delivered a poor sales growth of 11.6% over past five years."
        ]
    },
    "ALKEM": {
        "Title": "Alkem Laboratories Ltd share price | About Alkem Lab | Key Insights - Screener",
        "CompanyName": "Alkem Laboratories Ltd",
        "Link": "http://www.alkemlabs.com",
        "NSECode": "ALKEM",
        "BSECode": "539523",
        "AboutCompany": "Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)",
        "MarketCap": "56961",
        "P/ERatio": "26.4",
        "ROE": "19.4",
        "ROCE": "20.4",
        "DividendYeild": "0.94",
        "BookValue": "1,002",
        "LastPrice": "4764",
        "LastPriceChange": -2.22,
        "LastPriceChangeDate": "08 Aug",
        "High": "6,440",
        "Low": "4,492",
        "TotalAssets6Q": [
            [
                "Mar 2020",
                "9946"
            ],
            [
                "Mar 2021",
                "11519"
            ],
            [
                "Mar 2022",
                "14069"
            ],
            [
                "Mar 2023",
                "13757"
            ],
            [
                "Mar 2024",
                "15575"
            ],
            [
                "Mar 2025",
                "17691"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Dec 2023",
                "604"
            ],
            [
                "Mar 2024",
                "304"
            ],
            [
                "Jun 2024",
                "550"
            ],
            [
                "Sep 2024",
                "702"
            ],
            [
                "Dec 2024",
                "641"
            ],
            [
                "Mar 2025",
                "322"
            ]
        ],
        "PROs": [
            "Company has been maintaining a healthy dividend payout of 37.4%"
        ],
        "CONs": [
            "Promoter holding has decreased over last quarter: -2.09%",
            "The company has delivered a poor sales growth of 9.21% over past five years.",
            "Tax rate seems low"
        ]
    },
    "SANOFI": {
        "Title": "Sanofi India Ltd share price | About Sanofi India | Key Insights - Screener",
        "CompanyName": "Sanofi India Ltd",
        "Link": "http://www.sanofiindialtd.com",
        "NSECode": "SANOFI",
        "BSECode": "500674",
        "AboutCompany": "Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.",
        "MarketCap": "11974",
        "P/ERatio": "27.1",
        "ROE": "47.1",
        "ROCE": "49.2",
        "DividendYeild": "2.25",
        "BookValue": "374",
        "LastPrice": "5200",
        "LastPriceChange": 0.39,
        "LastPriceChangeDate": "08 Aug",
        "High": "7,600",
        "Low": "4,146",
        "TotalAssets6Q": [
            [
                "Dec 2023",
                "1715"
            ],
            [
                "Dec 2024",
                "1612"
            ]
        ],
        "TotalProfits6Q": [
            [
                "Sep 2023",
                "152"
            ],
            [
                "Dec 2023",
                "138"
            ],
            [
                "Mar 2024",
                "137"
            ],
            [
                "Jun 2024",
                "103"
            ],
            [
                "Sep 2024",
                "82"
            ],
            [
                "Dec 2024",
                "91"
            ]
        ],
        "PROs": [
            "Company is almost debt free.",
            "Company's working capital requirements have reduced from 27.6 days to 20.4 days"
        ],
        "CONs": [
            "Stock is trading at 13.9 times its book value",
            "Debtor days have increased from 32.9 to 41.7 days."
        ]
    }
}